MIMETAS

In this article, published in Angiogenesis, read about an innovative platform allows the vascularization of liver tissue in vitro, providing a significant leap forward in microphysiological systems. The study demonstrates the development of perfusable, vascularized liver models that acts as an alternative to animal grafting, offering a scalable and ethical alternative for drug testing and disease modeling. 🔬 Key Highlights: - Creation of a stable microvascular network capable of vascularizing liver spheroids and organoids. - Modeling of complex diseases like veno-occlusive disease in a liver context. - A promising tool for studying human liver regeneration, organogenesis, and drug responses. Read the full article here: https://lnkd.in/e-AEe6eM #LiverModels #Microfluidics #DrugTesting #LifeSciences #TissueEngineering

🌟Paul Vulto from MIMETAS is presenting on ‘High Content Imaging and Screening of Immunocompetent and Vascularized Liver-on-a-Chip Models’ at the Advanced Imaging and Organoid Technologies Meeting. His insightful talk explores the cutting-edge advancements in liver research, using these innovative models to enhance drug screening and deepen our understanding of liver function and disease. #ImgUserMeetingMD24 #Imaging #3DBiology #drugdiscovery #drugdevelopment

Looking for an advanced human in vitro liver model for your research? Check out our poster on "A comprehensive and scalable human liver-on-chip model for fibrosis drug discovery and gene delivery applications." MIMETAS's advanced 3D liver model mimics steatosis and fibrosis using multiple cell types (hepatocytes, endothelial, stellate, and immune cells), offering a powerful tool for studying liver health and disease. Compatible with automation and high-throughput screening, it’s paving the way for breakthroughs in therapies for liver diseases and cancer. 🔗 Download the poster now to learn more: https://lnkd.in/eanzwqam #LiverOnChip #FibrosisResearch #GeneDelivery #DrugDiscovery

📸 Snapshots from Drug Discovery 2024 (ELRIG UK), featuring Paul Vulto and Naomi den Breems with their posters! They'll be presenting both posters today (Wed, Oct 2, 17:00 - 17:30) and tomorrow (Thurs, Oct 3, 13:00 - 13:30). 📊 An automated and multiplexed liver fibrosis screening assay on a microfluidic liver model that replicates the cellular composition and organization of the hepatic lobule 📊 Influencing drug responses through in vitro tumor microenvironment characteristics Meet them there and learn what MIMETAS can do to support your drug discovery programs. https://lnkd.in/eNg9BcdJ

Join us at #DrugDiscovery2024 (ELRIG UK) in London on October 2-3 for Europe’s top drug discovery conference! We’re excited to showcase how MIMETAS can support your projects by humanizing drug discovery with our models. Be sure to check out our two poster presentations showcasing our latest advancements: 📌 MIMETAS Co-CEO Paul Vulto will be presenting Poster #105 "An automated and multiplexed liver fibrosis screening assay on a microfluidic liver model that replicates the cellular composition and organization of the hepatic lobule" 📌 Our Territory Manager Naomi den Breems will present poster #208 "Influencing drug responses through in vitro tumor microenvironment characteristics" Reach out to our attending experts to connect and discuss how we accelerate your drug discovery research! https://lnkd.in/eNg9BcdJ #DrugDiscovery #LiverModeling #TumorMicroenvironment #MicrophysiologicalSystems

Have you heard about Project SECRET? MIMETAS is a proud participant in this Horizon EU-funded initiative exploring the therapeutic potential of perinatal secretomes for treating neurological and cardiovascular disorders. As part of this doctoral network, MIMETAS will develop an optimized human 3D organoid-on-plate microfluidic platform for disease modelling and screening. By leveraging cutting-edge technologies and interdisciplinary approaches, SECRET seeks to unveil novel insights into the mechanisms underlying tissue regeneration and repair, offering hope for millions affected worldwide. Read more about the project here: https://lnkd.in/eSmwmebP #secretomes #CVD #neurologicaldisorders

⏰ Less than a week to register for our live webinar! If you're working in drug development and need more translatable models for compound screening, you won’t want to miss this. Upcoming Tuesday, September 24, MIMETAS experts Dr. Kinga Kosim, PhD and Brian Duggan will be presenting about the OrganoReady® Colon Organoid, the first ready-to-use stem cell-derived model, and how it is transforming intestinal toxicity screenings and drug development. Key topics: 🔬 Streamlining toxicology screenings with high-throughput assays 💊 Demonstrating toxicity events, like diarrhoeagenic effects 🦠 Modeling diseases like IBD for more accurate drug evaluation Register today: https://lnkd.in/g6M9dsH9 #GutToxicity #GItoxicity #Organoids #DrugDevelopment #Pharma

We have a new App Note! We're excited to share a breakthrough in predictive gastrointestinal (GI) toxicity research, in collaboration with Promega Corporation . It showcases how our newest product, the OrganoReady® Colon Organoid, combined with functional multiplexed assays, helps address a critical gap in drug development—predicting drug-induced GI adverse events. Key highlights: 🔬 Ready-to-use 3D human colon organoid 🧬 Translatable model for drug screening ⚙️ Predicts on-target & off-target toxicity with advanced assays Learn how to enhance your toxicology workflows and improve drug safety with this innovative gut model: https://lnkd.in/eXEFnxrr #Organoids #Toxicology #DrugDevelopment #GItoxicity #3DModels

Check out this exclusive interview with Dr. Jenna Moccia, Director of Product Management at STEMCELL Technologies and Dr. Bas Trietsch, Chief Technology Officer at MIMETAS! Together, they take a deep-dive into the world of drug discovery, exploring how stem cell-based models are impacting the current field and shaping its future. You can find the interview here: https://lnkd.in/ej4nRyqW #stemcells #3Dtissuemodels #drugdiscovery #microphysiologicalsystems 

📌🌺 MIMETAS is here in Hawaii for the 2024 ISSX/JSSX Meeting! Come meet Yoko Ejiri, Director of MIMETAS Japan at booth #12 to learn how our 3D human disease tissue models can enhance your research and enable more predictive and efficient drug discovery. Learn how to work with us: https://lnkd.in/ejpzYH2f #drugdiscovery #toxicology #drugsafety #ISSX2024 #JSSX2024